arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

Wednesday, May 28, 2014 1 min read

Key Takeaway: arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

Full Press Release Details

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO.